Billingsley, Caroline C <br/><br/>
Is it reasonable to administer pegfilgrastim on day 1 of a myelosuppressive chemotherapy regimen? A cost-utility analysis.  [electronic resource] 

 -  Cancer treatment and research communications  2018 
 - 21-25 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>2468-2942 
<br/><br/><label>Standard No.: </label>10.1016/j.ctarc.2017.11.003  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antineoplastic Agents--therapeutic use<br/>Cost-Benefit Analysis<br/>Drug Administration Schedule<br/>Febrile Neutropenia--chemically induced<br/>Female<br/>Filgrastim--administration & dosage<br/>Humans<br/>Ovarian Neoplasms--drug therapy<br/>Polyethylene Glycols--administration & dosage<br/>Primary Prevention<br/>Quality of Life<br/>Quality-Adjusted Life Years<br/>Risk Factors